Lamisil (Terbinafine Hydrochloride)

Terbinafine Hydrochloride blocks the fungal enzyme squalene epoxidase, preventing the synthesis of ergosterol, an essential component of fungal cell membranes. The resulting membrane disruption stops fungal growth and leads to cell death, while human cells are largely unaffected.

The specific dose and duration of Lamisil therapy are determined by the prescribing healthcare professional based on the type and severity of the infection, patient age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions exactly.

Safety data for terbinafine in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the prescriber in consultation with the patient.

To request Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals such as itraconazole or fluconazole, terbinafine has a different mechanism (squalene epoxidase inhibition) and often achieves higher cure rates for dermatophyte skin infections and onychomycosis. It is generally taken for a shorter period, but liver monitoring remains important.

Lamisil tablets should be stored at or below 25 °C (77 °F) in their original container, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Lamisil is taken orally as a tablet, usually with a full glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Swallow the tablet whole; do not crush or chew.

The most serious adverse events include liver toxicity, which may present as jaundice or elevated liver enzymes, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should report any signs of liver dysfunction or rash promptly to their healthcare provider.

Lamisil should be avoided in individuals with a known hypersensitivity to terbinafine or other allylamine antifungals, in patients with severe liver disease, and in children under the age recommended by the prescriber. Caution is also advised for patients taking multiple hepatotoxic drugs.